Healthcare provider profile · identity verified

Perry Michael Schall, M.D.

Internal Medicine · LA QUINTA, CA · NPI 1497779219

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	446	137
Amlodipine Besylate	Amlodipine Besylate	398	123
Atorvastatin Calcium	Atorvastatin Calcium	385	118
Levothyroxine Sodium	Levothyroxine Sodium	306	84
Losartan Potassium	Losartan Potassium	258	75
Tamsulosin Hcl	Tamsulosin Hcl	187	54
Pantoprazole Sodium	Pantoprazole Sodium	141	45
Metformin Hcl Er	Metformin Hcl	137	39
Mounjaro	Tirzepatide	136	20
Eliquis	Apixaban	135	36
Valsartan	Valsartan	126	33
Gabapentin	Gabapentin	121	41
Zolpidem Tartrate	Zolpidem Tartrate	114	35
Sertraline Hcl	Sertraline Hcl	107	34
Omeprazole	Omeprazole	102	32
Ozempic	Semaglutide	100	15
Alprazolam	Alprazolam	97	29
Prednisone	Prednisone	97	67
Trazodone Hcl	Trazodone Hcl	92	27
Metoprolol Succinate	Metoprolol Succinate	91	29
Azithromycin	Azithromycin	81	71
Lisinopril	Lisinopril	81	26
Lorazepam	Lorazepam	80	19
Metformin Hcl	Metformin Hcl	80	23
Famotidine	Famotidine	76	24
Hydrochlorothiazide	Hydrochlorothiazide	69	21
Simvastatin	Simvastatin	68	18
Synthroid	Levothyroxine Sodium	68	20
Montelukast Sodium	Montelukast Sodium	67	24
Potassium Chloride	Potassium Chloride	67	24
Escitalopram Oxalate	Escitalopram Oxalate	64	20
Pravastatin Sodium	Pravastatin Sodium	62	17
Allopurinol	Allopurinol	60	18
Paxlovid	Nirmatrelvir/Ritonavir	58	58
Diclofenac Sodium	Diclofenac Sodium	57	15
Ipratropium Bromide	Ipratropium Bromide	57	20
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	54	18
Alendronate Sodium	Alendronate Sodium	52	14
Furosemide	Furosemide	52	21
Jardiance	Empagliflozin	51	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	49	18
Clonazepam	Clonazepam	47	suppressed
Atenolol	Atenolol	44	12
Duloxetine Hcl	Duloxetine Hcl	44	13
Albuterol Sulfate Hfa	Albuterol Sulfate	43	33
Venlafaxine Hcl Er	Venlafaxine Hcl	42	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	41	13
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	41	14
Metoprolol Tartrate	Metoprolol Tartrate	40	12
Torsemide	Torsemide	40	14
Fluticasone Propionate	Fluticasone Propionate	39	24
Celecoxib	Celecoxib	38	16
Meloxicam	Meloxicam	37	17
Cephalexin	Cephalexin	36	28
Clopidogrel	Clopidogrel Bisulfate	36	13
Acyclovir	Acyclovir	34	12
Valacyclovir	Valacyclovir Hcl	33	16
Carvedilol	Carvedilol	32	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	30	suppressed
Citalopram Hbr	Citalopram Hydrobromide	30	suppressed
Finasteride	Finasteride	30	11
Testosterone	Testosterone	30	suppressed
Bupropion Xl	Bupropion Hcl	29	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Memantine Hcl	Memantine Hcl	29	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	26	23
Estradiol	Estradiol	26	12
Ezetimibe	Ezetimibe	26	13
Levofloxacin	Levofloxacin	26	20
Novolin R	Insulin Regular, Human	26	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	25	suppressed
Breo Ellipta	Fluticasone/Vilanterol	25	11
Temazepam	Temazepam	24	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	24	suppressed
Xarelto	Rivaroxaban	24	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	23	17
Farxiga	Dapagliflozin Propanediol	23	suppressed
Methylprednisolone	Methylprednisolone	23	13
Trulicity	Dulaglutide	23	suppressed
Azelastine Hcl	Azelastine Hcl	22	suppressed
Myrbetriq	Mirabegron	22	suppressed
Amoxicillin	Amoxicillin	21	11
Buspirone Hcl	Buspirone Hcl	21	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Ondansetron Hcl	Ondansetron Hcl	20	14
Tramadol Hcl	Tramadol Hcl	20	suppressed
Clonidine Hcl	Clonidine Hcl	19	suppressed
Ibandronate Sodium	Ibandronate Sodium	19	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	19	14
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	14
Acetaminophen-Codeine	Acetaminophen With Codeine	16	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	16	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	16	16
Felodipine Er	Felodipine	16	suppressed
Oxycodone Hcl	Oxycodone Hcl	16	suppressed
Propranolol Hcl	Propranolol Hcl	16	suppressed
Ramipril	Ramipril	16	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	15	suppressed
Hydrocortisone	Hydrocortisone	15	suppressed
Colchicine	Colchicine	14	suppressed
Irbesartan	Irbesartan	14	suppressed
Labetalol Hcl	Labetalol Hcl	14	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	14	suppressed
Pregabalin	Pregabalin	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Terazosin Hcl	Terazosin Hcl	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	11
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Verapamil Er	Verapamil Hcl	13	suppressed
Fluconazole	Fluconazole	12	suppressed
Januvia	Sitagliptin Phosphate	12	suppressed
Methenamine Hippurate	Methenamine Hippurate	12	suppressed
Zaleplon	Zaleplon	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Rybelsus	Semaglutide	11	suppressed
Warfarin Sodium	Warfarin Sodium	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error